Clinical Trial Experience
The CONFIRM (COmparisoN of FASLODEX In Recurrent or Metastatic breast cancer) Study1,2
CONFIRM (COmparisoN of FASLODEX In Recurrent or Metastatic breast cancer) was a phase III, randomized, double-blind, parallel-group, multicenter trial comparing fulvestrant 500 mg (n=362) and FASLODEX 250 mg (n=374) in postmenopausal women with estrogen receptor-positive advanced breast cancer who progressed or recurred following prior endocrine therapy.
Eligible patients were randomized 1:1 to fulvestrant 500 mg or FASLODEX 250 mg and assessed for tumor progression every 12 weeks. The primary objective was to compare the efficacy in both treatment groups in terms of progression-free survival.
Secondary objectives included
- Objective response rate (ORR)
- Overall survival
Safety was also assessed.
Take a closer look at the details and results.
Examine the study design
Learn about the efficacy of FASLODEX 500 mg
Read the safety profile for FASLODEX 500 mg
FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease
progression following antiestrogen therapy.
IMPORTANT SAFETY INFORMATION:
Click Here for Additional Safety Information
FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to
any of its components. Hypersensitivity reactions, including urticaria and angioedema have been reported in association with FASLODEX.
OnCue - News for
Regularly updated articles cover a range of topics including treatment information, oncology conferences details, and patient resources.
AZ ProCare Webcasts
Hear from disease-state experts about the treatment and management of HR+ metastatic breast cancer through live and archived Webcasts.